Skip to main content
SpringerLink
Log in

Eculizumab

5G1.1, h5G1.1, Long-Acting Anti-C5 Monoclonal Antibody 5G1-1, Long-Acting Anti-C5 Monoclonal Antibody 5G1.1

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

References

  1. Alexion Pharmaceuticals Inc. Alexion Pharmaceuticals Reports Second Quarter 2006 Results. Media Release: 8 Aug 2006. Available from: URL: http://www.alexionpharm.com

    Google Scholar 

  2. Alexion Pharmaceuticals Inc. Alexion Submits Market Authorization Application for Soliris(TM) (eculizumab) in the Treatment of Paroxysmal Nocturnal Hemoglobinuria to the European Medicines Agency. Media Release: 26 Sep 2006. Available from URL: http://www.alexionpharm.com

    Google Scholar 

  3. Alexion Pharmaceuticals Inc. Alexion Pharmaceuticals Reports Positive Phase III Results for Eculizumab From Pivotal TRIUMPH Efficacy Trial in Paroxysmal Nocturnal Hemoglobinuria Patients. Media Release: 26 Jan 2006. Available from URL: http://www.alexionpharm.com

    Google Scholar 

  4. Alexion Pharmaceuticals Inc. Alexion Pharmaceuticals Initiates Treatment in SHEPHERD, Its Second Phase III Eculizumab Trial in Paroxysmal Nocturnal Hemoglobinuria Patients. Media Release: 10 Jan 2005. Available from URL: http://www.alexionpharm.com

    Google Scholar 

  5. Alexion Pharmaceuticals Inc. Alexion Pharmaceuticals Reports Positive Interim Safety and Efficacy Results for Soliris(TM) (eculizumab) From the Open-Label Phase III SHEPHERD Safety Trial in Paroxysmal Nocturnal Hemoglobinuria Patients. Media Release: 12 Jun 2006. Available from URL: http://www.alexionpharm.com

    Google Scholar 

  6. Alexion Pharmaceuticals Inc. One Year Cumulative Results of Alexion Pharmaceuticals’ Ongoing Clinical Trial in Paroxysmal Nocturnal Hemoglobinuria Presented at the British Society of Haematology Annual Meeting. Media Release: 20 Apr 2004. Available from URL: http://www.alexionpharm.com

    Google Scholar 

  7. Alexion Pharmaceuticals Inc. Alexion Pharmaceuticals Reports Two-Year Safety and Efficacy Data of Chronic Eculizumab Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria. Media Release: 7 Dec 2004. Available from URL: http://www.alexionpharm.com

    Google Scholar 

  8. Alexion Pharmaceuticals Inc. Alexion Pharmaceuticals Receives Orphan Drug Designation in the U.S. and Europe for Eculizumab in PNH. Media Release: 8 Dec 2003. Available from URL: http://www.alexionpharm.com

    Google Scholar 

  9. Wang Y, Rollins SA, Madri JA, et al. Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease. Proceedings of the National Academy of Sciences of the United States of America 92: 8955–8959, 12 Sep 1995

    Article  PubMed  CAS  Google Scholar 

  10. Alexion Pharmaceuticals Inc. Alexion Issued Key Patent for Eculizumab in Japan. Media Release: 13 Feb 2006. Available from URL: http://www.alexionpharm.com

    Google Scholar 

  11. Alexion Pharmaceuticals Inc. Alexion Reports Results of Eculizumab Trial in New England Journal of Medicine. Media Release: 4 Feb 2004. Available from URL: http://www.alex-ionpharm.com

    Google Scholar 

  12. Alexion Pharmaceuticals Inc. Alexion Announces Results of Clinical Trial in Paroxysmal Nocturnal Hemoglobinuria Presented at the American Society of Hematology Annual Meeting. Media Release: 9 Dec 2002. Available from URL: http://www.alexionpharm.com

    Google Scholar 

  13. Alexion announces positive clinical results from phase I/II study of C5 complement inhibitor in rheumatoid arthritis patients. PR Newswire [online]: 3 pages, 22 Apr 1999. Available from URL: http://www.newspage.com

  14. Alexion Pharmaceuticals Inc. Alexion announces completion of phase I psoriasis pilot safety study. Media Release: 3 pages, 7 Jun 2001. Available from URL: http://www.alxn.com

    Google Scholar 

  15. Alexion Pharmaceuticals Inc. ALEXION completes phase I dermatomyositis pilot safety study. Media Release: 2 pages, 20 Dec 2001. Available from URL: http://www.alexionpharm.com

    Google Scholar 

  16. Alexion Pharmaceuticals Inc. Alexion Reports Presentation of Membranous Nephritis Clinical Trials. Media Release: 4 Nov 2002. Available from URL: http://www.alexionpharm.com

    Google Scholar 

  17. Alexion Pharmaceuticals Inc. Alexion Reports Preliminary Results of its Phase IIb Rheumatoid Arthritis Clinical Trial. Media Release: 28 Jan 2004. Available from URL: http://www.alexionpharm.com

    Google Scholar 

  18. Wang Y, Hu O, Kristan J. Subcutaneous administration of anti-C5 monoclonal antibody induces systemic complement inhibition and ameliorates immune complex mediated inflammatory responses. Arthritis and Rheumatism 39 (Suppl.): 245, Sep 1996

    Article  Google Scholar 

  19. Kroshus TJ, Rollins SA, Dalmasso AP. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation. Transplantation 60: 1194–1202, 15 Dec 1995

    PubMed  CAS  Google Scholar 

  20. Hillmen P, Hall C, Marsh JCW, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. New England Journal of Medicine 350: 552–559, No. 6, 5 Feb 2004

    Article  PubMed  CAS  Google Scholar 

  21. Alexion Pharmaceuticals Inc. Alexion initiates phase II efficacy study of C5 complement inhibitor in kidney disease patients. Media Release: 3 pages, 12 Aug 1999

    Google Scholar 

  22. Alexion Pharmaceuticals Inc. Alexion reports interim analysis of clinical safety and efficacy data from phase II rheumatoid arthritis trial. Media Release: 3 pages, 29 Jan 2001. Available from URL: http://www.alxn.com

    Google Scholar 

  23. Mojcik CF, Kremer J, Bingham C, et al. Results of a phase 2B study of the humanized anti-c5 antibody eculizumab in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 63 (Suppl. 1): 301, Jul 2004

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eculizumab. Drugs R D 8, 61–68 (2007). https://doi.org/10.2165/00126839-200708010-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200708010-00006

Keywords

Search

Navigation